Rimantadin Kids syrup for children, 100ml

Prevention and early treatment of influenza A in children over 1 year old.

Prophylaxis with rimantadine can be effective when people come into contact with sick people at home, when infection spreads in closed groups, and when there is a high risk of getting sick during an influenza epidemic.

Treatment scheme:

It is taken orally (after meals), washed down with water, according to the following scheme: for children from 1 year to 3 years old - on the first day, 10 ml (2 teaspoons) of syrup (20 mg) 3 times a day (daily dose - 60 mg) ; 2 and 3 days - 10 ml 2 times a day (daily dose - 40 mg), 4 days - 5 days - 10 ml once a day (daily dose - 20 mg).

Children from 3 to 7 years old - on the first day - 15 ml (3 teaspoons) of syrup (30 mg) 3 times a day (daily dose - 90 mg); 2 and 3 days - 3 teaspoons 2 times a day (daily dose - 60 mg), 4 days - 5 days - 3 teaspoons 1 time a day (daily dose - 30 mg). Children from 7 to 10 years old, 25 ml (5 teaspoons) of syrup (50 mg) 2 times a day for 5 days (daily dose - 100 mg).

Children from 11 to 14 years old, 25 ml (5 teaspoons) of syrup (50 mg) 3 times a day for 5 days (daily dose - 150 mg).

Preventive scheme:

For prevention use: children from 1 to 3 years old - 10 ml (2 teaspoons) of syrup (20 mg) once a day, children from 3 to 7 years old - 15 ml (3 teaspoons) of syrup (30 mg) once a day, children over 7 years old - 25 ml (5 teaspoons) of syrup (50 mg) once a day for 10-15 days.

Attention! The daily dose of rimantadine should not exceed 5 mg per kg of body weight.

Active substance:

rimantadine hydrochloride - 2.0 mg

Excipients: sorbitol (liquid sorbitol) - 514.3 mg, maltitol (liquid maltitol) - 514.3 mg, sodium carmellose - 3.64 mg, methyl parahydroxybenzoate - 1.15 mg, strawberry flavor - 0.63 mg, purified water - up to 1 ml.

Х Acute liver disease;

Х acute and chronic kidney disease;

Х thyrotoxicosis;

Х pregnancy and the period of breastfeeding;

Х children under 1 year old;

Х hypersensitivity to rimantadine and drug components;

Х deficiency of sucrase / isomaltase;

Х glucose-galactose malabsorption;

Х fructose intolerance.

Carefully

Epilepsy (including history), severe chronic renal failure, liver failure, diabetes mellitus. Due to the presence of sorbitol in the composition, it should be taken with caution in vomiting, pain and discomfort in the abdomen, diarrhea.

Pharmacological properties

Pharmacodynamics

Rimantadine - an antiviral agent derived from adamantane; active against various strains of influenza A. As a weak base, rimantadine acts by increasing the pH of endosomes, which have a membrane of vacuoles that surround viral particles after they enter the cell. Prevention of acidification in these vacuoles blocks the fusion of the viral envelope with the endosome membrane, thus preventing the transfer of viral genetic material into the cytoplasm of the cell. Rimantadine also inhibits the release of viral particles from the cell, i.e. interrupts the transcription of the viral genome.

Pharmacokinetics

After oral administration, rimantadine is almost completely absorbed in the intestine. Absorption is slow. The connection with plasma proteins is about 40%. Volume of distribution: adults - 17-25 l / kg, children - 289 l / kg. The concentration in the nasal secretion is 50% higher than the plasma concentration. The value of the maximum concentration of rimantadine in blood plasma (Cmax) when taking 100 mg once a day is 181 ng / ml, 100 mg twice a day is 416 ng / ml. It is metabolized in the liver. Half-life (T1 / 2) - 24-36 hours; excreted by the kidneys 15% - unchanged, 20% - in the form of hydroxyl metabolites. In chronic renal failure, T1 / 2 increases by 2 times. In persons with renal insufficiency and in the elderly, it can accumulate in toxic concentrations if the dose is not corrected in proportion to the decrease in creatinine clearance.

Application during pregnancy and during breastfeeding

The use of the drug is contraindicated in pregnancy. If necessary, use during lactation should stop breastfeeding.

Side effect

From the side of the cardiovascular system: tachycardia, heart failure, heart block, palpitations, arterial hypertension, cerebrovascular accident, loss of consciousness. From the nervous system: insomnia, dizziness, headache, irritability, fatigue, impaired concentration, movement disorders, drowsiness, depressed mood, euphoria, hyperkinesia, tremors, hallucinations, confusion, convulsions. From the senses: tinnitus, change or loss of smell. From the respiratory system: shortness of breath, bronchospasm, cough. From the gastrointestinal tract: nausea, vomiting, loss of appetite, dryness of the oral mucosa, abdominal pain, diarrhea, dyspepsia. On the part of the skin and subcutaneous tissue: rash. Others: tiredness.

Overdose

In some cases, when the recommended dose is exceeded, there are observed: tearing of the eyes and pain in the eyes, frequent urination, fever, constipation, sweating, inflammation of the oral mucosa, dry skin. Treatment: gastric lavage, symptomatic therapy: measures to maintain vital functions. Rimantadine is partially excreted during hemodialysis.

Interaction with other medicinal products

Pharmacodynamic:

rimantadine reduces the effectiveness of antiepileptic drugs.

Pharmacokinetic:

adsorbents, astringents and coating agents reduce the absorption of rimantadine. Urine acidifying agents (acetazolamide, sodium bicarbonate, etc.) increase the concentration of rimantadine. Paracetamol and ascorbic acid reduce the maximum plasma concentration of rimantadine by 11%. Cimetidine reduces the clearance of rimantadine by 18%. The sorbitol contained in the drug can affect the bioavailability of concurrently used drugs. Due to the increased risk of dyspeptic symptoms, concomitant use with other medicinal products containing sorbitol is not recommended.

special instructions

The use of rimantadine for 2-3 days before and 6-7 hours after the onset of clinical manifestations of type A influenza reduces the severity of symptoms of the disease and the degree of serological reaction. Some therapeutic effect may also occur if rimantadine is given within 18 hours of the onset of the first flu symptoms. When applied, an exacerbation of chronic concomitant diseases is possible. In patients with epilepsy, on the background of the use of rimantadine, the risk of developing an epileptic seizure increases. 15 ml of syrup corresponds to 1 bread unit (XE), which should be taken into account when prescribing the drug to patients with diabetes mellitus. The emergence of drug-resistant viruses is possible. Sorbitol can cause abdominal discomfort and laxative effects. If such effects develop during treatment,the drug should be discontinued and a doctor should be consulted. Due to the increased risk of dyspeptic symptoms, it is not recommended to take it simultaneously with food containing large amounts of sorbitol (prunes, etc.).

Influence on the ability to drive vehicles and mechanisms

Given the likelihood of side effects from the central nervous system, care should be taken when driving vehicles and mechanisms.